Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24011571 | 0.89 | EPHX1 (0.50) | EPHX1DRD4TP53MCHR1TACR1 | |
| SCHEMBL26633732 | 0.78 | RAB9A (0.53) | EPHX1DRD4MCHR1HPGD | |
| SCHEMBL30634146 | 0.78 | L3MBTL1 (0.47) | EPHX1HPGDMEN1KMT2A | |
| SCHEMBL26633678 | 0.78 | L3MBTL1 (0.47) | EPHX1HPGDMEN1KMT2A | |
| SCHEMBL24011706 | 0.74 | EPHX1 (0.47) | EPHX1DRD4TP53MCHR1HPGD | |
| SCHEMBL30288079 | 0.74 | EPHX1 (0.59) | EPHX1DRD4TP53HPGDMEN1 | |
| SCHEMBL24011134 | 0.74 | EPHX1 (0.61) | EPHX1DRD4TP53HPGDMEN1 | |
| SCHEMBL26633681 | 0.73 | EPHX1 (0.64) | EPHX1DRD4TP53MCHR1HPGD | |
| SCHEMBL26633933 | 0.73 | EPHX1 (0.57) | EPHX1DRD4TP53HPGDMEN1 | |
| SCHEMBL26633846 | 0.73 | EPHX1 (0.57) | EPHX1DRD4TP53HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843295-B | NAMPT modulators | 赛特凯恩蒂克公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115843295-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-4146640-A2 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | EPHX1 3913/4885DRD4 3923/4885TP53 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.